

Resource Summary Report

Generated by [PRECISE-TBI](#) on Jul 31, 2026

GSE4922

RRID:SCR_003557

Type: Tool

Proper Citation

GSE4922 (RRID:SCR_003557)

Resource Information

URL: <http://ranchobiosciences.com/gse4922/>

Proper Citation: GSE4922 (RRID:SCR_003557)

Description: Curated data set of a study that investigated the expression profiles of 347 primary invasive breast tumors on Affymetrix microarrays. Three separate breast cancer cohorts were analyzed: 1) Uppsala (n=249), 2) Stockholm (n=58), 3) Singapore (n=40). The Uppsala and Singapore data can be accessed in GSE4922. The Stockholm cohort data can be accessed at GEO Series GSE1456.

Abbreviations: GSE4922

Resource Type: data or information resource, data set

Keywords: adult human, expression profile, breast

Related Condition: Cancer, Breast cancer, Tumor

Availability: Free, Public

Resource Name: GSE4922

Resource ID: SCR_003557

Alternate IDs: nlx_157796

Record Creation Time: 20220129T080219+0000

Record Last Update: 20260728T043148+0000

Ratings and Alerts

No rating or validation information has been found for GSE4922.

No alerts have been found for GSE4922.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 110 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Xu J, et al. (2025) FRMD8 inhibits tumor metastasis in BRCA1-associated TNBC by negatively regulating tmTNF-?. Cellular & molecular biology letters, 30(1), 76.

Huang X, et al. (2025) Association of DBNDD1 with prognostic and immune biomarkers in invasive breast cancer. Discover oncology, 16(1), 218.

Han JY, et al. (2025) Cytoplasmic HMGB1 promotes the activation of JAK2-STAT3 signaling and PD-L1 expression in breast cancer. Molecular medicine (Cambridge, Mass.), 31(1), 197.

Liao M, et al. (2024) BCAR4 Expression as a Predictive Biomarker for Endocrine Therapy Resistance in Breast Cancer. Clinical breast cancer, 24(4), 368.

Jacobs C, et al. (2024) HSF1 Inhibits Antitumor Immune Activity in Breast Cancer by Suppressing CCL5 to Block CD8+ T-cell Recruitment. Cancer research, 84(2), 276.

Hjorth M, et al. (2024) Decorin, an exercise-induced secretory protein, is associated with improved prognosis in breast cancer patients but does not mediate anti-tumorigenic tissue crosstalk in mice. Journal of sport and health science, 14, 100991.

Giannakakis A, et al. (2024) KDM7A-DT induces genotoxic stress, tumorigenesis, and progression of p53 missense mutation-associated invasive breast cancer. Frontiers in oncology, 14, 1227151.

Saatci O, et al. (2024) Targeting LINC00152 activates cAMP/Ca²⁺/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer. Cell death & disease, 15(6), 418.

Mendiburu-Eliçabe M, et al. (2024) NCAPH drives breast cancer progression and identifies a gene signature that predicts luminal a tumour recurrence. Clinical and translational medicine, 14(2), e1554.

Park IA, et al. (2024) p27 Cell Cycle Inhibitor and Survival in Luminal-Type Breast Cancer: Gene Ontology, Machine Learning, and Drug Screening Analysis. Journal of breast cancer, 27(5), 305.

Kim HS, et al. (2023) Low CDKN1B Expression Associated with Reduced CD8+ T Lymphocytes Predicts Poor Outcome in Breast Cancer in a Machine Learning Analysis. Journal of personalized medicine, 14(1).

Ditz JC, et al. (2023) COmic: convolutional kernel networks for interpretable end-to-end learning on (multi-)omics data. *Bioinformatics (Oxford, England)*, 39(39 Suppl 1), i76.

Mendiburu-Eliçabe M, et al. (2023) NCAPH Drives Breast Cancer Progression and Identifies a Gene Signature that Predicts Luminal A Tumor Recurrence. *Research square*.

Mascia F, et al. (2022) In search of autophagy biomarkers in breast cancer: Receptor status and drug agnostic transcriptional changes during autophagy flux in cell lines. *PLoS one*, 17(1), e0262134.

Qing T, et al. (2022) Molecular differences between younger versus older ER-positive and HER2-negative breast cancers. *NPJ breast cancer*, 8(1), 119.

Habara M, et al. (2022) FKBP52 and FKBP51 differentially regulate the stability of estrogen receptor in breast cancer. *Proceedings of the National Academy of Sciences of the United States of America*, 119(15), e2110256119.

Fu H, et al. (2022) High expression of CCNB1 driven by ncRNAs is associated with a poor prognosis and tumor immune infiltration in breast cancer. *Aging*, 14(16), 6780.

Yang Y, et al. (2022) NARF is a hypoxia-induced coactivator for OCT4-mediated breast cancer stem cell specification. *Science advances*, 8(49), eabo5000.

Guo Q, et al. (2022) Mammary collagen is under reproductive control with implications for breast cancer. *Matrix biology : journal of the International Society for Matrix Biology*, 105, 104.

Zhang H, et al. (2021) HMGB1 is a key factor for tamoxifen resistance and has the potential to predict the efficacy of CDK4/6 inhibitors in breast cancer. *Cancer science*, 112(4), 1603.